Journal: Journal for Immunotherapy of Cancer
Article Title: Brain tumors induce immunoregulatory dendritic cells in draining lymph nodes that can be targeted by OX40 agonist treatment
doi: 10.1136/jitc-2025-011548
Figure Lengend Snippet: CCR7+OX40+ dendritic cells (DCs) in cervical lymph nodes correlate with anti-OX40 agonist immunotherapy. DCs from TdLNs were isolated and cultured in the presence of the labeled peptide DQ-OVA, which allowed for quantification of antigen uptake, processing, and presentation. (A, B) Representative histograms and percentages of DQ-OVA signals in different DC populations. (C) DCs from TdLN were cultured as in (A) and incubated in the presence of anti-OX40 agonist, Poly-I:C or IgG control. The percentages of CD40 (C), CD86 (D), and PDL-1 (E) were calculated. (F) The percentage of CCR7+OX40+ DCs was calculated from TdLNs harvested 12 days post-tumor inoculation. (G) Representative immunofluorescence staining images of brain sections showing LAMP3+ (*), CD4+ (+), and OX40+ (¤). (H) The graph shows the average number of positive cells across different regions of interest (ROIs, n=392). (I, J) Kaplan-Meier survival curves of EG7-OVA tumor-bearing mice treated with agonistic OX40 antibody or IgG control, either alone or combined with FTY720, were analyzed using the log-rank test (n=5–7 mice/group test). Statistical analyses were conducted using the Mann-Whitney U test. Bar graphs show the mean±SD; two-way ANOVA with Tukey’s correction: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ANOVA, analysis of variance TdLNs, tumor-draining lymph nodes.
Article Snippet: The following stimuli were added: Poly-I:C 5 μg/mL (Adipogen Life Sciences), αCD40 (FGK45), αIL-6 (MP5-20F3), αIL-4 (BVD6-24G2), αOX40 (OX-86), αCD200 (OX-90), and αPDL-1 (10F.9G2TM) (BioXcell) at a concentration of 100 ng/mL.
Techniques: Isolation, Cell Culture, Labeling, Incubation, Control, Immunofluorescence, Staining, MANN-WHITNEY